Factors Associated With Major Bleeding Events
Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar ris...
Gespeichert in:
Veröffentlicht in: | Journal of the American College of Cardiology 2014-03, Vol.63 (9), p.891-900 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 900 |
---|---|
container_issue | 9 |
container_start_page | 891 |
container_title | Journal of the American College of Cardiology |
container_volume | 63 |
creator | Goodman, Shaun G., MD, MSc Wojdyla, Daniel M., MS Piccini, Jonathan P., MD White, Harvey D., MB, ChB, DSc Paolini, John F., MD, PhD Nessel, Christopher C., MD Berkowitz, Scott D., MD Mahaffey, Kenneth W., MD Patel, Manesh R., MD Sherwood, Matthew W., MD Becker, Richard C., MD Halperin, Jonathan L., MD Hacke, Werner, MD Singer, Daniel E., MD Hankey, Graeme J., MD Breithardt, Gunter, MD Fox, Keith A.A., MB, ChB Califf, Robert M., MD |
description | Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category ( |
doi_str_mv | 10.1016/j.jacc.2013.11.013 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1645324143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0735109713062086</els_id><sourcerecordid>3557385571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</originalsourceid><addsrcrecordid>eNp9kE1Lw0AURQdRsFb_gKuA68T3Mpl8gAi1tCpUXKi4HGYmLzoxJnUmLfTfm1BBcOHqbu55H4exc4QIAdPLOqqVMVEMyCPEaIgDNkEh8pCLIjtkE8i4CBGK7JideF8DQJpjMWHhUpm-cz6Yed8Zq3oqg1fbvwcPqu5ccNMQlbZ9CxZbant_yo4q1Xg6-8kpe1kunud34erx9n4-W4WGi6wPK65L0oLrSlWp5pqDhjwXPNFZUiY5FDwHoiSuwFSm1LnArEKugcCUaakUn7KL_dy167425HtZdxvXDislpongcYIJH1rxvmVc572jSq6d_VRuJxHkqEXWctQiRy0SUQ4xQFd7iIb7t5ac9MZSa4Y3HZlelp39H7_-g5vGttao5oN25H_PlD6WIJ9G76N25JDGkKf8G4mnfvY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645324143</pqid></control><display><type>article</type><title>Factors Associated With Major Bleeding Events</title><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Goodman, Shaun G., MD, MSc ; Wojdyla, Daniel M., MS ; Piccini, Jonathan P., MD ; White, Harvey D., MB, ChB, DSc ; Paolini, John F., MD, PhD ; Nessel, Christopher C., MD ; Berkowitz, Scott D., MD ; Mahaffey, Kenneth W., MD ; Patel, Manesh R., MD ; Sherwood, Matthew W., MD ; Becker, Richard C., MD ; Halperin, Jonathan L., MD ; Hacke, Werner, MD ; Singer, Daniel E., MD ; Hankey, Graeme J., MD ; Breithardt, Gunter, MD ; Fox, Keith A.A., MB, ChB ; Califf, Robert M., MD</creator><creatorcontrib>Goodman, Shaun G., MD, MSc ; Wojdyla, Daniel M., MS ; Piccini, Jonathan P., MD ; White, Harvey D., MB, ChB, DSc ; Paolini, John F., MD, PhD ; Nessel, Christopher C., MD ; Berkowitz, Scott D., MD ; Mahaffey, Kenneth W., MD ; Patel, Manesh R., MD ; Sherwood, Matthew W., MD ; Becker, Richard C., MD ; Halperin, Jonathan L., MD ; Hacke, Werner, MD ; Singer, Daniel E., MD ; Hankey, Graeme J., MD ; Breithardt, Gunter, MD ; Fox, Keith A.A., MB, ChB ; Califf, Robert M., MD ; ROCKET AF Investigators</creatorcontrib><description>Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (<65, 65 to 74, ≥75 years; pinteraction = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP <90 mm Hg were associated with a decreased risk. Conclusions Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767 )</description><identifier>ISSN: 0735-1097</identifier><identifier>EISSN: 1558-3597</identifier><identifier>DOI: 10.1016/j.jacc.2013.11.013</identifier><language>eng</language><publisher>New York: Elsevier Inc</publisher><subject>Anticoagulants ; atrial fibrillation ; Blood pressure ; Cardiac arrhythmia ; Cardiology ; Cardiovascular ; Confidence intervals ; Diabetes ; Drug dosages ; Drug therapy ; Embolisms ; Heart failure ; hemorrhage ; Hepatitis ; Hypertension ; Internal Medicine ; Nervous system ; Older people ; Risk factors ; Stroke</subject><ispartof>Journal of the American College of Cardiology, 2014-03, Vol.63 (9), p.891-900</ispartof><rights>American College of Cardiology Foundation</rights><rights>2014 American College of Cardiology Foundation</rights><rights>Copyright Elsevier Limited Mar 11, 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</citedby><cites>FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jacc.2013.11.013$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids></links><search><creatorcontrib>Goodman, Shaun G., MD, MSc</creatorcontrib><creatorcontrib>Wojdyla, Daniel M., MS</creatorcontrib><creatorcontrib>Piccini, Jonathan P., MD</creatorcontrib><creatorcontrib>White, Harvey D., MB, ChB, DSc</creatorcontrib><creatorcontrib>Paolini, John F., MD, PhD</creatorcontrib><creatorcontrib>Nessel, Christopher C., MD</creatorcontrib><creatorcontrib>Berkowitz, Scott D., MD</creatorcontrib><creatorcontrib>Mahaffey, Kenneth W., MD</creatorcontrib><creatorcontrib>Patel, Manesh R., MD</creatorcontrib><creatorcontrib>Sherwood, Matthew W., MD</creatorcontrib><creatorcontrib>Becker, Richard C., MD</creatorcontrib><creatorcontrib>Halperin, Jonathan L., MD</creatorcontrib><creatorcontrib>Hacke, Werner, MD</creatorcontrib><creatorcontrib>Singer, Daniel E., MD</creatorcontrib><creatorcontrib>Hankey, Graeme J., MD</creatorcontrib><creatorcontrib>Breithardt, Gunter, MD</creatorcontrib><creatorcontrib>Fox, Keith A.A., MB, ChB</creatorcontrib><creatorcontrib>Califf, Robert M., MD</creatorcontrib><creatorcontrib>ROCKET AF Investigators</creatorcontrib><title>Factors Associated With Major Bleeding Events</title><title>Journal of the American College of Cardiology</title><description>Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (<65, 65 to 74, ≥75 years; pinteraction = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP <90 mm Hg were associated with a decreased risk. Conclusions Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767 )</description><subject>Anticoagulants</subject><subject>atrial fibrillation</subject><subject>Blood pressure</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular</subject><subject>Confidence intervals</subject><subject>Diabetes</subject><subject>Drug dosages</subject><subject>Drug therapy</subject><subject>Embolisms</subject><subject>Heart failure</subject><subject>hemorrhage</subject><subject>Hepatitis</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Nervous system</subject><subject>Older people</subject><subject>Risk factors</subject><subject>Stroke</subject><issn>0735-1097</issn><issn>1558-3597</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><recordid>eNp9kE1Lw0AURQdRsFb_gKuA68T3Mpl8gAi1tCpUXKi4HGYmLzoxJnUmLfTfm1BBcOHqbu55H4exc4QIAdPLOqqVMVEMyCPEaIgDNkEh8pCLIjtkE8i4CBGK7JideF8DQJpjMWHhUpm-cz6Yed8Zq3oqg1fbvwcPqu5ccNMQlbZ9CxZbant_yo4q1Xg6-8kpe1kunud34erx9n4-W4WGi6wPK65L0oLrSlWp5pqDhjwXPNFZUiY5FDwHoiSuwFSm1LnArEKugcCUaakUn7KL_dy167425HtZdxvXDislpongcYIJH1rxvmVc572jSq6d_VRuJxHkqEXWctQiRy0SUQ4xQFd7iIb7t5ac9MZSa4Y3HZlelp39H7_-g5vGttao5oN25H_PlD6WIJ9G76N25JDGkKf8G4mnfvY</recordid><startdate>20140311</startdate><enddate>20140311</enddate><creator>Goodman, Shaun G., MD, MSc</creator><creator>Wojdyla, Daniel M., MS</creator><creator>Piccini, Jonathan P., MD</creator><creator>White, Harvey D., MB, ChB, DSc</creator><creator>Paolini, John F., MD, PhD</creator><creator>Nessel, Christopher C., MD</creator><creator>Berkowitz, Scott D., MD</creator><creator>Mahaffey, Kenneth W., MD</creator><creator>Patel, Manesh R., MD</creator><creator>Sherwood, Matthew W., MD</creator><creator>Becker, Richard C., MD</creator><creator>Halperin, Jonathan L., MD</creator><creator>Hacke, Werner, MD</creator><creator>Singer, Daniel E., MD</creator><creator>Hankey, Graeme J., MD</creator><creator>Breithardt, Gunter, MD</creator><creator>Fox, Keith A.A., MB, ChB</creator><creator>Califf, Robert M., MD</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20140311</creationdate><title>Factors Associated With Major Bleeding Events</title><author>Goodman, Shaun G., MD, MSc ; Wojdyla, Daniel M., MS ; Piccini, Jonathan P., MD ; White, Harvey D., MB, ChB, DSc ; Paolini, John F., MD, PhD ; Nessel, Christopher C., MD ; Berkowitz, Scott D., MD ; Mahaffey, Kenneth W., MD ; Patel, Manesh R., MD ; Sherwood, Matthew W., MD ; Becker, Richard C., MD ; Halperin, Jonathan L., MD ; Hacke, Werner, MD ; Singer, Daniel E., MD ; Hankey, Graeme J., MD ; Breithardt, Gunter, MD ; Fox, Keith A.A., MB, ChB ; Califf, Robert M., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c357t-f3bdeb53bfaf6b3b30b088534b74d4809380ee42f0cfcdb8517f13b0e0cd6daa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Anticoagulants</topic><topic>atrial fibrillation</topic><topic>Blood pressure</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular</topic><topic>Confidence intervals</topic><topic>Diabetes</topic><topic>Drug dosages</topic><topic>Drug therapy</topic><topic>Embolisms</topic><topic>Heart failure</topic><topic>hemorrhage</topic><topic>Hepatitis</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Nervous system</topic><topic>Older people</topic><topic>Risk factors</topic><topic>Stroke</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goodman, Shaun G., MD, MSc</creatorcontrib><creatorcontrib>Wojdyla, Daniel M., MS</creatorcontrib><creatorcontrib>Piccini, Jonathan P., MD</creatorcontrib><creatorcontrib>White, Harvey D., MB, ChB, DSc</creatorcontrib><creatorcontrib>Paolini, John F., MD, PhD</creatorcontrib><creatorcontrib>Nessel, Christopher C., MD</creatorcontrib><creatorcontrib>Berkowitz, Scott D., MD</creatorcontrib><creatorcontrib>Mahaffey, Kenneth W., MD</creatorcontrib><creatorcontrib>Patel, Manesh R., MD</creatorcontrib><creatorcontrib>Sherwood, Matthew W., MD</creatorcontrib><creatorcontrib>Becker, Richard C., MD</creatorcontrib><creatorcontrib>Halperin, Jonathan L., MD</creatorcontrib><creatorcontrib>Hacke, Werner, MD</creatorcontrib><creatorcontrib>Singer, Daniel E., MD</creatorcontrib><creatorcontrib>Hankey, Graeme J., MD</creatorcontrib><creatorcontrib>Breithardt, Gunter, MD</creatorcontrib><creatorcontrib>Fox, Keith A.A., MB, ChB</creatorcontrib><creatorcontrib>Califf, Robert M., MD</creatorcontrib><creatorcontrib>ROCKET AF Investigators</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of the American College of Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goodman, Shaun G., MD, MSc</au><au>Wojdyla, Daniel M., MS</au><au>Piccini, Jonathan P., MD</au><au>White, Harvey D., MB, ChB, DSc</au><au>Paolini, John F., MD, PhD</au><au>Nessel, Christopher C., MD</au><au>Berkowitz, Scott D., MD</au><au>Mahaffey, Kenneth W., MD</au><au>Patel, Manesh R., MD</au><au>Sherwood, Matthew W., MD</au><au>Becker, Richard C., MD</au><au>Halperin, Jonathan L., MD</au><au>Hacke, Werner, MD</au><au>Singer, Daniel E., MD</au><au>Hankey, Graeme J., MD</au><au>Breithardt, Gunter, MD</au><au>Fox, Keith A.A., MB, ChB</au><au>Califf, Robert M., MD</au><aucorp>ROCKET AF Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors Associated With Major Bleeding Events</atitle><jtitle>Journal of the American College of Cardiology</jtitle><date>2014-03-11</date><risdate>2014</risdate><volume>63</volume><issue>9</issue><spage>891</spage><epage>900</epage><pages>891-900</pages><issn>0735-1097</issn><eissn>1558-3597</eissn><abstract>Objectives This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). Background The ROCKET AF trial demonstrated similar risks of stroke/systemic embolism and major/nonmajor clinically relevant bleeding (principal safety endpoint) with rivaroxaban and warfarin. Methods The risk of the principal safety and component bleeding endpoints with rivaroxaban versus warfarin were compared, and factors associated with major bleeding were examined in a multivariable model. Results The principal safety endpoint was similar in the rivaroxaban and warfarin groups (14.9 vs. 14.5 events/100 patient-years; hazard ratio: 1.03; 95% confidence interval: 0.96 to 1.11). Major bleeding risk increased with age, but there were no differences between treatments in each age category (<65, 65 to 74, ≥75 years; pinteraction = 0.59). Compared with those without (n = 13,455), patients with a major bleed (n = 781) were more likely to be older, current/prior smokers, have prior gastrointestinal (GI) bleeding, mild anemia, and a lower calculated creatinine clearance and less likely to be female or have a prior stroke/transient ischemic attack. Increasing age, baseline diastolic blood pressure (DBP) ≥90 mm Hg, history of chronic obstructive pulmonary disease or GI bleeding, prior acetylsalicylic acid use, and anemia were independently associated with major bleeding risk; female sex and DBP <90 mm Hg were associated with a decreased risk. Conclusions Rivaroxaban and warfarin had similar risk for major/nonmajor clinically relevant bleeding. Age, sex, DBP, prior GI bleeding, prior acetylsalicylic acid use, and anemia were associated with the risk of major bleeding. (An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation: NCT00403767 )</abstract><cop>New York</cop><pub>Elsevier Inc</pub><doi>10.1016/j.jacc.2013.11.013</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0735-1097 |
ispartof | Journal of the American College of Cardiology, 2014-03, Vol.63 (9), p.891-900 |
issn | 0735-1097 1558-3597 |
language | eng |
recordid | cdi_proquest_journals_1645324143 |
source | Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
subjects | Anticoagulants atrial fibrillation Blood pressure Cardiac arrhythmia Cardiology Cardiovascular Confidence intervals Diabetes Drug dosages Drug therapy Embolisms Heart failure hemorrhage Hepatitis Hypertension Internal Medicine Nervous system Older people Risk factors Stroke |
title | Factors Associated With Major Bleeding Events |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T06%3A46%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20Associated%20With%20Major%20Bleeding%20Events&rft.jtitle=Journal%20of%20the%20American%20College%20of%20Cardiology&rft.au=Goodman,%20Shaun%20G.,%20MD,%20MSc&rft.aucorp=ROCKET%20AF%20Investigators&rft.date=2014-03-11&rft.volume=63&rft.issue=9&rft.spage=891&rft.epage=900&rft.pages=891-900&rft.issn=0735-1097&rft.eissn=1558-3597&rft_id=info:doi/10.1016/j.jacc.2013.11.013&rft_dat=%3Cproquest_cross%3E3557385571%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645324143&rft_id=info:pmid/&rft_els_id=1_s2_0_S0735109713062086&rfr_iscdi=true |